Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Recurrent episodes of recall dermatitis of irradiated breast after LHRH agonist administration.

Kostadima L, Pentheroudakis G, Pavlidis N.

J BUON. 2011 Jan-Mar;16(1):183-4. No abstract available.

PMID:
21674876
[PubMed - indexed for MEDLINE]
2.

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.

Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE.

J Clin Oncol. 2004 Sep 15;22(18):3694-9.

PMID:
15365065
[PubMed - indexed for MEDLINE]
3.

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R.

Lancet. 2007 May 19;369(9574):1711-23.

PMID:
17512856
[PubMed - indexed for MEDLINE]
4.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer.

J Clin Oncol. 2001 Jan 15;19(2):343-53.

PMID:
11208825
[PubMed - indexed for MEDLINE]
5.

Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer.

Matsumoto M, Miyauchi M, Yamamoto N, Shishikura T, Imanaka N.

Breast Cancer. 2000;7(3):237-40.

PMID:
11029804
[PubMed - indexed for MEDLINE]
6.

Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.

Curry EA 3rd, Sweeney CJ.

J Urol. 2002 Jul;168(1):193. No abstract available.

PMID:
12050525
[PubMed - indexed for MEDLINE]
7.

Drug eruption induced by gonadotropin-releasing hormone analogs accompanying radiation-recall phenomenon.

Oshima M, Murao K, Ishigami T, Kubo Y.

J Dermatol. 2012 Dec;39(12):1080-1. doi: 10.1111/j.1346-8138.2012.01576.x. Epub 2012 May 9. No abstract available.

PMID:
22568476
[PubMed - indexed for MEDLINE]
8.

[Adverse reaction of LH-RH agonist and its countermeasure].

Oishi K.

Nihon Rinsho. 2000 Jul;58 Suppl:202-5. Review. Japanese. No abstract available.

PMID:
11022714
[PubMed - indexed for MEDLINE]
9.

Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

Jonat W.

Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S23-6: discussion S33-5. Review.

PMID:
12353820
[PubMed - indexed for MEDLINE]
10.

Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

Michaud LB, Buzdar AU.

Drugs Aging. 2000 Apr;16(4):261-71. Review.

PMID:
10874521
[PubMed - indexed for MEDLINE]
11.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.

J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46.

PMID:
14679153
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

[The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex)].

Ivanov S, Ivanov S.

Akush Ginekol (Sofiia). 1998;37(4):25-6. Bulgarian.

PMID:
10360048
[PubMed - indexed for MEDLINE]
14.

The role of ovarian ablation in the adjuvant therapy of breast cancer.

Tan SH, Wolff AC.

Curr Oncol Rep. 2008 Jan;10(1):27-37. Review.

PMID:
18366958
[PubMed - indexed for MEDLINE]
15.

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.

PMID:
10223480
[PubMed - indexed for MEDLINE]
16.

[Effectiveness of LH-RH agonist for bone metastases of breast cancer--report of a case].

Kudoh S, Kawamura H, Suzuki Y, Matsuzaki M, Nishina M, Tsukamoto M.

Gan To Kagaku Ryoho. 1996 May;23(6):787-90. Japanese.

PMID:
8645031
[PubMed - indexed for MEDLINE]
17.

Fertility preservation in (breast) cancer patients: is it safe?

Wildiers H, Neven P, Amant F, D'hooghe T, Paridaens R.

J Clin Oncol. 2006 Nov 20;24(33):5335-6; author reply 5337-8. No abstract available.

PMID:
17114672
[PubMed - indexed for MEDLINE]
18.

Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.

Cheer SM, Plosker GL, Simpson D, Wagstaff AJ.

Drugs. 2005;65(18):2639-55. Review.

PMID:
16392882
[PubMed - indexed for MEDLINE]
19.

[A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].

Hisamatsu K, Iwamori S, Minami K, Tanabe K, Ota K, Akiyama H.

Gan To Kagaku Ryoho. 1997 Aug;24(10):1327-30. Japanese. Erratum in: Gan To Kagaku Ryoho 1997 Sep;24(11):1590.

PMID:
9279354
[PubMed - indexed for MEDLINE]
20.

Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer: the ZEBRA experience.

Jonat W.

Eur J Cancer. 2002 Nov;38 Suppl 6:S39-40. No abstract available.

PMID:
12409069
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk